Clinical Research Directory

Inclusion Criteria: * Pediatric patients aged between 4 and 6 years at the time of screening. * Formally diagnosed with drug-resistant focal epilepsy according to the International League Against Epilepsy (ILAE) criteria (failure of adequate trials of two or more tolerated, appropriately chosen, and appropriately used antiepileptic drug regimens). * Experiencing a baseline frequency of at least 3 clinical seizures per week, documented via a reliable prospective seizure diary kept by parents or caregivers. * Patients whose legal guardians are willing and able to provide written informed consent, and patients who can provide assent when age-appropriate. Exclusion Criteria: * Presence of metallic implants in the brain or skull (e.g., surgical clips, cochlear implants) near the site of electrode placement. * History of severe cardiac arrhythmias, unstable cardiovascular disease, or baseline pacemaker dependent, which may compromise safety during Heart Rate Variability (HRV) monitoring. * Progressive neurological disorders, neurodegenerative diseases, or active brain tumors. * Recent changes in antiepileptic drug (AED) dosages or types within the 4 weeks prior to baseline screening. * Any active skin lesions, inflammation, or structural cranial abnormalities at the target electrode site that prevent safe application of the tDCS pads. * Current participation in another clinical trial involving investigational drugs or neurostimulation devices.